From Financial Modeling Prep: 2025-01-02 08:16:00

Sangamo Therapeutics (NASDAQ: SGMO) saw its stock drop 56% after Pfizer ended their partnership to co-develop a gene therapy for hemophilia A. Pfizer’s decision was based on limited patient interest and slow adoption of gene therapies for hemophilia A. Sangamo now has full rights to the program but faces delays in regulatory approval.

Late-stage trial results showed the therapy’s potential to reduce bleeding episodes in hemophilia A patients. However, Pfizer’s withdrawal means plans to submit regulatory approval data by early 2025 are on hold. Sangamo is now looking for new collaboration opportunities or alternative pathways for development. Trial participants will remain under observation until April 21, 2025.



Read more at Financial Modeling Prep:: Sangamo Shares Plummet 56% as Pfizer Ends Hemophil…